Immunogenetic associations of scleroderma-related antinuclear antibodies
Article first published online: 9 DEC 2005
Copyright © 1990 American College of Rheumatology
Arthritis & Rheumatism
Volume 33, Issue 5, pages 657–665, May 1990
How to Cite
Genth, E., Mierau, R., Genetzky, P., Von Mühlen, C. A., Kaufmann, S., Wilmowsky, H. V., Meurer, M., Krieg, T., Pollmann, H.-J. and Hartl, P. W. (1990), Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis & Rheumatism, 33: 657–665. doi: 10.1002/art.1780330508
- Issue published online: 9 DEC 2005
- Article first published online: 9 DEC 2005
- Manuscript Accepted: 14 DEC 1989
- Manuscript Received: 19 SEP 1989
- Verein zur Förderung der Rheumaforschung bei der Rheumaklinik Aachen e.V.
Patients selected for the presence of sclerodermarelated antibodies (anti-DNA-topoisomerase I [antitopo I; n = 43], anticentromere antibody [ACA; n = 63], or anti-Pm-Scl [n = 12]) were studied for class I and class II major histocompatibility complex antigens, as well as for Gm and Km allotypes. Anti-topo I was associated with HLA-DR5 (70% of patients versus 30.6% of controls; Pcorr = 0.0018, relative risk [RR] = 5.3). All patients with anti-Pm-Scl were positive for HLA-DR3 (versus 23.5% of controls; Pcorr < 0.001); 6 of these patients were DR3/4 heterozygous (50% versus 3.5% of controls; Pcorr < 0.001, RR = 27.3). Patients with ACA were frequently positive for HLA-DR1, DR4, or DRw8, with 73.7% demonstrating at least 1 of these alleles (versus 41.2% of controls; Pcorr = 0.0152, RR = 4.0). This group of ACA-positive patients who had DR1, DR4, and/or DRw8 consisted mainly of a subgroup of patients with rheumatoid arthritis. We conclude that different class II major histocompatibility complex antigens influence the formation of anti-topo I and anti-Pm-Scl. Important clinical differences between these patient groups and the immunogenetic heterogeneity support the notion of different antibody-defined scleroderma subsets.